In February, Aratana raised $12m in its series C round.

Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.

Ambit plans to list 4.645 million shares at between $13 and $15 each when it floats on the Nasdaq stock exchange.

OrbiMed and Novo are providing $35m of debt, with SKr95m ($15m) of equity from OrbiMed and a number of institutional investors.

BB Biotech Ventures, a fund advised by Swiss investment bank Bellevue Group, and Novartis Venture Fund led the C round.